Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 62

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Tardive dyskinesia

Not yet recruiting

Study on the Effects of (+)-α-Dihydrotetrabenazine for Treating Tardive Dyskinesia in Patients with Schizophrenia, Mood, or Gastrointestinal Disorders

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:(2R,3R,11Br)-1,3,4,6,7,11B-Hexahydro-9,10-Dimethoxy-3-(2-Methylpropyl)-2H-Benzo[A]Quinolizin-2-Ol
  • Sponsor:Adeptio Pharmaceuticals Limited

Glioma

Not yet recruiting

Study of L19TNF (onfekafusp alfa) with temozolomide chemoradiotherapy for newly diagnosed glioblastoma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Diabetic foot

Not yet recruiting

Study on the Safety and Effects of Udonitrectag for Treating Diabetic Foot Ulcers in Patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:UDONITRECTAG
  • Sponsor:Mimetech S.r.l.

Herpes simplex meningitis

Not yet recruiting

Study on Aciclovir and Valaciclovir for Treating HSV-2 Meningitis in Adults

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Aalborg University Hospital

Duchenne muscular dystrophy

Not yet recruiting

Study on the Safety and Effectiveness of DT-DEC01 for Patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Sponsor:Dystrogen Therapeutics Technology Polska Sp. z o.o.

Ischaemic stroke

Not yet recruiting

Study of dabigatran, apixaban and edoxaban for prevention of stroke recurrence in patients with acute ischemic stroke without known atrial fibrillation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Universitaetsspital Basel

Anal incontinence

Not yet recruiting

Study on the Safety and Effectiveness of Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells for Treating Fecal Incontinence in Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells Expanded
  • Sponsor:Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salud

Study on the Effectiveness of Etoposide Phosphate, Carboplatin, Methotrexate, Rituximab, and Cyclophosphamide in Patients with Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Oulu University Hospital

Carotid artery stenosis

Not yet recruiting

Study on Carotid Stenosis: Evaluating Evolocumab for Plaque Stabilization and Regression in Patients with Carotid Artery Narrowing

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Azienda Ospedaliera Ordine Mauriziano Di Torino

Diabetic foot+1

Not yet recruiting

Study on the Effectiveness of Autologous Bone Marrow-Derived Mononuclear Cells and Angioplasty in Diabetic Patients with Chronic Limb-Threatening Ischemia

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS BONE MARROW-DERIVED MONONUCLEAR CELLS
  • Sponsor:Institute For Clinical And Experimental Medicine

Myasthenia gravis

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Muscular dystrophy

Not yet recruiting

Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Deflazacort
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.